Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Korro Bio (Nasdaq: KRRO) granted a newly hired employee an option to purchase 1,000 common shares, effective November 11, 2026.

The option has an exercise price of $14.41 per share, matching the closing share price on the grant date, and a ten-year term. It vests over four years: 25% on the first anniversary of the employee’s start date and the remaining 75% in 36 equal monthly installments, subject to continued service at each vesting date. The independent Compensation Committee approved the grant under the 2026 Inducement Plan as an employment inducement under Nasdaq Listing Rule 5635(c)(4).

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Employee option covering 1,000 common shares at $14.41 per share creates potential dilution upon exercise.

Key Figures

Option shares: 1,000 shares Exercise price: $14.41 per share Option term: 10 years +1 more

Option shares

1,000 shares

Grant to one newly hired employee

Exercise price

$14.41 per share

Set at the closing price on the grant effective date

Option term

10 years

Term of the granted option

Vesting schedule

4 years; 25% initially, then 75% in 36 monthly installments

Subject to continued service through each applicable vesting date

Historical Context

1 past event · Latest: Oct 16

1 event

1. Oct 16

   Inducement grant

   24h Move

   +5.0%

   Prior employee option grants used the same ten-year term and four-year vesting structure.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-statutory stock option, nasdaq listing rule 5635(c)(4)

2 terms

non-statutory stock option financial

"grant of a non-statutory stock option to one newly hired employee"

A non-statutory stock option is a company-granted right that lets a person buy shares later at a set price but does not receive special tax-favored treatment under tax law. It matters to investors because when the option is used the holder usually pays ordinary income tax on the gain and the company records compensation cost and issues new shares, which can reduce existing owners’ percentage ownership—think of it like a coupon to buy stock that creates a taxable event and some dilution.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA^®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of a non-statutory stock option to one newly hired employee.

Korro granted the new employee a nonstatutory stock option to purchase 1,000 shares of Korro’s common stock at an exercise price of $14.41 per share, the closing price per share of Korro's common stock as reported by Nasdaq on the grant effective date, November 11, 2026. The option has a ten-year term and vests over four years, with 25% of the shares vesting on the first anniversary of the employee’s start date and the remaining 75% vesting in 36 equal monthly installments on each monthly anniversary thereafter until the fourth anniversary of the employee’s start date, subject to the employee’s continued service with Korro through each applicable vesting date.

This grant was approved by Korro’s independent Compensation Committee pursuant to Korro’s 2026 Inducement Plan and was made as an inducement material to the employee’s acceptance of employment with Korro in accordance with Nasdaq Listing Rule 5635(c)(4).

About Korro

Korro is a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA^®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases. OPERA provides precise, tissue-directed delivery of oligonucleotides that modify the targeted native mRNA transcript to repair or form a de-novo protein with enhanced functionality. The platform combines a suite of capabilities consisting of sophisticated knowledge of transcription biology through ADAR proteins (Adenosine Deaminases Acting on RNA), machine learning optimization of oligonucleotides, linker chemistry expertise, along with use of a highly targeted tissue-specific delivery methodology.  As such, the OPERA platform has enabled Korro to generate and advance a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, providing precise yet transient single base edits to produce therapeutic proteins with augmented activity versus its endogenous counterpart. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary OPERA platform with precedented delivery modalities, including N-acetylgalactosamine (GalNAc) conjugated for delivery for subcutaneous administration, manufacturing know-how, and established regulatory pathways of approved oligonucleotide medicines. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.

Korro Bio Contact Information  

Investor & Media Contact 
Malini Chatterjee, Ph.D
Blueprint Life Science Group
mchatterjee@bplifescience.com or ir@korrobio.com
917.330.4269

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the terms of Korro Bio’s November 2026 employee stock option grant?

The grant covers 1,000 common shares at an exercise price of $14.41 per share, effective November 11, 2026, with a ten-year term. Vesting occurs over four years: 25% on the first anniversary of the employee’s start date and the remaining 75% in 36 equal monthly installments, subject to continued service through each vesting date.